HEDIS® MEASURES Pediatric & Adolescent Provider Matrix



HEDIS® MEASURES Pediatric & Adolescent Provider Matrix

HEDIS[®] measures are used to gauge the quality of care health plan members are receiving. This matrix provides measure specific information for needed services and directions on how to close gaps in the care of your members. *Utilizing proper coding practices is the best way to close member gaps in your Care Opportunity Report and reduces the need for medical record reviews.

You may have relevant information regarding a member that you are unable to submit via claim. In this case, you can close the gap by submitting the medical record indicating the member has already received the relevant service or has a condition that excludes them from the measure. All medical records should be faxed to AvMed Corporate Quality Improvement at 1-800-331-3843.

PREVENTION AND SCREENING

Measure	Member Population	Screening, Test or Care Needed	How You Can P Preferred Method	revent or Close Gap * Acceptable Method	
Childhood Immunization Status (CIS) Combo 10	Children age 2	Administered all doses of the following vaccines before child's 2nd birthday: 4 DtaP 3 IPV 1 MMR 3 HiB 3 HepB 1 Vzv 4 Pneumococcal conjugate 1 HepA 3 Rotavirus (2 if administer 2-dose version, OR 3 if administer 3-dose version) 2 Influenza	appointment to come for a visit of The following CPT codes indicate DtaP - 90700, 90721, 90723 IPV - 90713, 90698, 90723 MMR - 90707, 90710 HiB - 90644-90648, 90721, Hep B - 90723, 90740, 9074 Vzv - 90710, 90716 PCV - 90669, 90670 Hep A - 90633 Rotavirus - 90681, 90680 Influenza - 90655, 90657,900	e an Immunization: 3, 90698 90748, 90698	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)
Chlamydia Screening in Women (CHL)	Sexually active women age 16-24	A Chlamydia test every year	Consider routine Chlamydia screening using a urine sample for all sexually active female members in this age range Screen at least once a year during any visit (sick or well visit) Take the opportunity to counsel and educate all members, including adolescents, on STDs The following CPT codes indicate a Chlamydia screening: 87110, 87270, 87320, 87490-87492, 87810	Contact members on your Care Opportunity Report and confirm they've had their Well Women's visit If member had a screening in the current year, document the date and result, if available. Submit the medical record to AvMed If member has not had a screening , consider scheduling the member's OB/GYN visit while they are on the phone to increase likelihood the member receives a Chlamydia screening If the member is an adolescent due for a wellness visit, schedule visit and use it as an opportunity to screen for Chlamydia and educate on STDs	Adult BMI Assessment (ABA)

Note: The Adult BMI Assessment (ABA) measure can be used for members that have not transitioned from pediatric care to Adult PCP/FP

PREVENTION AND SCREENING (Cont.)

			··/		
AvMed	Measure	Member Population	Screening, Test or Care Needed	How You Can Prev Preferred Method	vent or Close Gap * Acceptable Method
is case, you can close the gap as a condition that excludes them 1-800-331-3843. revent or Close Gap * Acceptable Method	Immunizations for Adolescents (IMA) (combo 2)	Adolescents ages 9-13	Adminster the following on or between member's 11th and 13th birthdays: 1 meningococcal vaccine AND 10th and 13th birthdays: 1 tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap) AND 9th and 13th birthdays: 2 HPV vaccinations at least 146 days apart OR 3 HPV vaccinations on different dates of service	Contact members on your Co schedule an appointment to Immunizations. The following CPT codes indi Tdap - 90715 HPV - 90649, 90650, 9065 Meningococcal - 90644, 90 If the member already had re an anaphylactic or other adv document the date. Submit n the vaccines to AvMed when	come for a visit and get their icate an Immunization: 1 734 quired vaccine or has had erse reaction to the vaccine, nedical record with notation of
nd get Immunizations. an Immunization: 6, 90698 90748, 90698 4, 90747, 90748 661, 90662, 90673, 90685,90687	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)	Children age 3-17	Conduct the following at least once a year from ages 2 to 18 years: BMI percentile documentation AND Counseling for Nutrition AND Counseling for Physical Activity	Submit the following codes on the claim: BMI Percentile ICD-10: Z68.51 - Z68.54 Nutritional Counseling: Procedure Codes G0270 S9449 97802 G0271 S9452 97803 G0447 S9470 97804	Document all three components on the Member's medical record at least once a year. Submit medical record documentation to AvMed upon request. Medical record must show some discussion of nutrition and physicial activity and the BMI must be plotted or show the percentile.
ne(s), or has had an anaphylactic or ne, document the date(s). Submit accines to AvMed when requested.				ICD-10: Z71.3 Physical Activity Counseling: S9451 ICD-10 Z02.5 G0447	
Contact members on your Care Opportunity Report and confirm they've had their Well Women's visit If member had a screening in the current year, document the date and result, if available. Submit the medical record to AvMed If member has not had a screening , consider scheduling the member's OB/GYN visit while they are on the phone to increase likelihood the member receives a Chlamydia screening If the member is an adolescent due for a wellness visit, schedule visit and use it as an opportunity to screen for Chlamydia and educate on STDs	Adult BMI Assessment (ABA)	Ages 18-74	For members 18-20: a BMI percentile, weight, AND height documented every 1-2 years.	Include appropriate diagnosis code on claim for every visit to indicate weight was measured and BMI value or BMI percentile was documented: ICD 10 BMI %tile: Z68.51 - Z68.54	Be sure to measure and document weight, height, BMI percentile on every patient's record at least once a year. Submit medical record showing weight, height, and BMI percentile measured during the current year, upon AvMed's request.

RESPIRATORY CONDITIONS

Measure	Member	Screening, Test or	How You Can Pre	event or Close Gap *
	Population	Care Needed	Preferred Method	Acceptable Method
Appropriate Testing for Children With Pharyngitis (CWP)	Children age 2-18 who were diagnosed with pharyngitis, tonsillitis or strep throat AND were dispensed an antibiotic	Administer a group A streptococcus (strep) test within three days of diagnosis	Administer or order a strep test for children with throat infections when prescribing an antibiotic Include code for strep test on claim: 87070 87650 87071 87651 87081 87652 87430 87880	Administer or order a strep test for children with throat infections when prescribing an antibiotic: Document type, date and result of strep test on medico record. Submit medical record to AvMed upon request.
Appropriate Treatment for Children With Upper Respiratory Infection (URI)	Children age 3 months -18 years with an upper respiratory infection	Avoid prescribing an antibiotic if the only diagnosis is an upper respiratory infection.	If an upper respiratory infection is the only condition, avoid writing an antibiotic prescription.	If prescribing an antibiotic for a bacterial infection (or co-morbid condition), use diagnosis code for bacterial infection and/or co-morbid condition when submitting claim. Code any secondary conditions.
Asthma Medication Ratio (AMR)**	Members age 5-64 with persistent asthma	At least 50% or greater of all asthma medications filled should be controller medications.	Take the opportunity at every a your members about the impo medications to control their as Inquire about and address, wh adherence the member may be effects, costs, or perceptions to	rtance of taking controller thma. here possible any barrier to e experiencing such as side
Medication Management for People with Asthma (MMA)**	Members age 5-85 with persistent asthma	Adherence to asthma controller medication for at least 75% (preferred) or 50% of their treatment period. Treatment period starts the date of the first filled asthma prescription and ends the last day of the year.	Take the opportunity at every a members about the importanc medications. Inquire about and address, wh adherence the member may be effects, costs, perceptions towo	e of taking prescribed here possible, any barrier to e experiencing such as side
BEHAVIORAL HEA	ALTH CONDITIONS			
Follow-Up Care for Children Prescribed ADHD Medication (ADD)	Children ages 6-12 who had prescription for ADHD	Initiation Phase: At least one follow-up visit with practitioner with prescribing authority during 30-day Initiation Phase. <i>Continuation and Maintenance</i> <i>(C&M) Phase:</i> At least two additional follow-up visits with a practitioner within 270 days (9 months) after Initiation Phase ended.	Contact members on your Car schedule appointments to com Submit claims showing memb Use applicable CPT Codes who	ne for follow up visits. Ners had follow up visits.

*This document represents only a set of recommendations to be implemented or acted upon by the physician as she/he deems appropriate. The physician and not AvMed is engaged in the practice of medicine. The physician maintains at all times the only physician/patient relationship with the Member. The judgments and decisions related to medical care, including but not limited to diagnosis, treatment, classification, identification, coding, etc. remain wholly within the province and control of the physician. Physicians must comply with all laws and regulations, including those related to fraud, waste, and abuse.

**See Relevant Medications table.

***See CIS and WCC informational worksheets.

RELEVANT MEDICATIONS BY MEASURE

* nod	ADHD Medications Description	Prescription
a strep n throat	CNS stimulants	Amphetamine- dextroaphetamine
ribing	Alpha 2 receptor agonists	 Dexmethylphenidate
	Miscellaneous ADHD	Clonidine
al	medications	Atomoxetine
	Asthma Controller Medicat	ions
	Antiasthmatic combinations	• Dyphylline-guaifenesin • Guaife
ic	Antibody inhibitor	• Omalizumab
(or	Inhaled steroid combinations	Budesonide-formoterol Flutico
se	Inhaled corticosteroids	Beclomethasone Budesonide
erial Did	Leukotriene modifiers	• Montelukast • Zafirlukast • Zileu
ng	Mast cell stabilizers	Cromolyn
ry	Methylxanthines	Aminophylline Dyphylline T
	Asthma Reliever Medicatio	ns
	Short-acting inhaled beta-2 agonists	Abuterol • Levalbuterol • Pirbuterol •
o de	VACCINATION & WELL CH	HILD FORMS & TOOLS

Vaccination	
Child and Adolescent Vaccination Forms	Contraindication S
Notification of Vaccination Patient Form Addressing Parents about HPV	Children & Teens I
ő	Children & Teens I
For more up to date forms:	

http://www.cdc.gov/vaccines

Well Child

BMI Chart for plotting (paper medical record)

Note: EMR systems require you to turn on the BMI percentile and if plotting, the BMI %, percentile must be present.

Nutrition Counseling:

- If paper medical record, provide discussion of nutrition.
- EMR use check boxes

Physical Activity Counseling

- If paper medical record, provide discussion of physical activity.
- EMR use check boxes

- Dextroamphetamine
- Methylphenidate
- Lisdexamfetamine
- Methamphetamine
- Guanfacine

ifenesin-theophylline

- casone-salmeterol Mometasone-formoterol
- le Ciclesonide Flunisolide Fluticasone CFC free Mometasone euton
- Theophylline

loretu

Screening Checklist:

Form

Information for Healthcare Professional

(Page 1 of 2)

Vaccine Administration Record for Children and Teens

Birthdate:	
Clinic name and address	

Patient name:

Before administering any vaccines, give copies of all pertinent Vaccine Information Statements (VISs) to the child's parent or legal representative and

Chart number:_

Vaccine Administration Record for Children and Teens

Before administering any vaccines, give copies of all pertinent Vaccine Information Statements (VISs) to the child's parent or legal representative and of the vaccine(s). Always provide or update the patient's personal record card.

Vaccine	Type of	Date given	Funding Source							Source		Route & Site ³	Vacci	ne		formation ent (VIS)	Vaccinator⁵ (signature or		Type of	
	Vaccine ¹	(mo/day/yr)	(F,S,P)²	a Sile"	Lot #	Mfr.	Date on VIS ^₄	Date given⁴	initials & title)	Vaccine	Vaccine ¹	(
epatitis B ⁶										Measles, Mumps,										
.g., HepB, Hib-HepB, TaP-HepB-IPV)										Rubella ⁶ (e.g., MMR,										
ive IM. ³										MMRV) Give SC. ³										
-										Varicella ⁶ (e.g., VAR,										
phtheria, Tetanus,										MMRV) Give SC. ³		-								
rtussis ⁶ g., DTaP, DTaP/Hib,										Hepatitis A ⁶										
aP-HepB-IPV, DT,										(HepA) Give IM. ³		_								
aP-IPV/Hib, Tdap,												_								
CaP-IPV, Td) ve IM. ³																				
-										Meningococcal (e.g.,										
-										MenACWY-CRM; Men- ACWY-D; Hib-MenCY;										
laemophilus influen-			+		_				MPSV4) Give MenACWY		_									
e type b ⁶						_				and Hib-MenCY IM ³ and		_								
g., Hib, Hib-HepB,										give MPSV4 SC. ³										
FaP-IPV/Hib, DTaP/Hib, b-MenCY) Give IM. ³						_				Human papillomavirus ⁶										
,										(e.g., HPV2, HPV4) Give IM. ³										
blio ⁶ g., IPV, DTaP-HepB-										Give IIVI.		_								
aP-IPV/Hib, DTaP-IPV)																				
ve IPV SC or IM. ³										Influenza (e.g., IIV3, trivalent inacti-										
ve all others IM. ³										vated; IIV4, quadrivalent in-										
neumococcal										activated; RIV, recombinant		_								
g., PCV7, PCV13, con- gate; PPSV23, polysac-										inactivated [for ages 18–49 yrs]; LAIV4, quadrivalent										
aride)										live attenuated)										
ve PCV IM. ³										Give IIV and RIV IM. ³ Give LAIV IN. ³										
ve PPSV SC or IM. ³										Give LATV IN.										
otavirus (RV1, RV5)																				
ve orally (po). ³										Other		+								
F				+ +		-	1													

DTaP

DT (pediatric)

DTaP/Hib

DTaP-IPV/Hib

DTaP-IPV

HepA-HepB

Hib-HepB

Hib-MenCY

HepB

Hib

IPV

PCV13

PPSV23

RV1

RV5

Tdap

Td

DTaP-HepB-IPV Pediarix (GSK)

Abbreviation Trade Name and Manufacturer

Generic DT (sanofi pasteur)

TriHIBit (sanofi pasteur)

Pentacel (sanofi pasteur)

Engerix-B (GSK); Recombivax HB (Merck)

Adacel (sanofi pasteur); Boostrix (GSK)

Twinrix (GSK), can be given to teens age 18 and older

ActHIB (sanofi pasteur); Hiberix (GSK); PedvaxHIB (Merck)

Decavac (sanofi pasteur); Generic Td (MA Biological Labs) For additional copies, visit www.immunize.org/catg.d/p2022.pdf • Item #P2022 (4/14)

Kinrix (GSK)

Comvax (Merck)

MenHibrix (GSK)

Ipol (sanofi pasteur)

Prevnar 13 (Pfizer)

Rotarix (GSK)

RotaTeg (Merck)

Pneumovax 23 (Merck)

Daptacel (sanofi); Infanrix (GlaxoSmithKline [GSK]); Tripedia (sanofi pasteur)

How to Complete This Record

- 1. Record the generic abbreviation (e.g., Tdap) or the trade name for each vaccine (see table at right).
- 2. Record the funding source of the vaccine given as either F (federal), S (state), or P (private).
- 3. Record the route by which the vaccine was given as either intramuscular (IM), subcutaneous (SC), intradermal (ID), intranasal (IN), or oral (PO) and also the site where it was administered as either RA (right arm), LA (left arm), RT (right thigh), or LT (left thigh).
- 4. Record the publication date of each VIS as well as the date the VIS is given to the patient.
- 5. To meet the space constraints of this form and federal requirements for documentation, a healthcare setting may want to keep a reference list of vaccinators that includes their initials and titles.
- 6. For combination vaccines, fill in a row for each antigen in the combination.

Technical content reviewed by the Centers for Disease Control and Prevention

This form was created by the Immunization Action Coalition • www.immunize.org • www.vaccineinformation.org

How to Complete This Record

- 1. Record the generic abbreviation (e.g., Tdap) or the trade name for each table at right).
- 2. Record the funding source of the vaccine given as either F (federal P (private).
- 3. Record the route by which the vaccine was given as either intran subcutaneous (SC), intradermal (ID), intranasal (IN), or oral (PO) at where it was administered as either RA (right arm), LA (left arm), R or LT (left thigh).
- 4. Record the publication date of each VIS as well as the date the VIS patient.
- 5. To meet the space constraints of this form and federal requirements tion, a healthcare setting may want to keep a reference list of vaccinato their initials and titles.
- 6. For combination vaccines, fill in a row for each antigen in the combination.

Technical content reviewed by the Centers for Disease Control and Prevention

This form was created by the Immunization Action Coalition • www.immunize.org • www.vaccineinformation.org

Patient name:

Birthdate:

Chart number:

Clinic name and address

	7 1	1	1	<u> </u>		
Funding Source	Route & Site ³	Vaccin	e		nformation ent (VIS)	Vaccinator⁵ (signature or initials & title)
(F,S,P)²	a one	Lot #	Mfr.	Date on VIS ^₄	Date given⁴	initials & title)
	1					1

See page 1 to record hepatitis B, diphtheria, tetanus, pertussis, Haemophilus influenzae type b, polio, pneumococcal, and rotavirus vaccines.

	Abbreviation	Trade Name and Manufacturer
1 • /	MMR	MMRII (Merck)
ach vaccine (see	VAR	Varivax (Merck)
	MMRV	ProQuad (Merck)
al), S (state), or	НерА	Havrix (GlaxoSmithKline [GSK]); Vaqta (Merck)
	НерА-НерВ	Twinrix (GSK)
muscular (IM),	HPV2	Cervarix (GSK)
	HPV4	Gardasil (Merck)
and also the site RT (right thigh),	LAIV (Live attenuated influenza vaccine]	FluMist (MedImmune)
S is given to the	TIV (Trivalent inactivat- ed influenza vaccine); RIV (Recombinant influenza vaccine)	Afluria (CSL Biotherapies); Agriflu (Novartis); Fluarix (GSK); Flublok (Protein Sciences Corp.); Flucelvax (Novartis); FluLaval (GSK); Fluvini (Novartis); Fluzone, Fluzone Intradermal [for ages 18–64 yrs] (sanofi)
for documenta- ors that includes	MCV4 or MenACWY, MenACWY-CRM, MenACWY-D; Hib-MenCY	MenACWY-D = Menactra (sanofi pasteur); MenACWY-CRM = Menveo (Novartis); Hib-MenCY (MenHibrix [GSK])
	MPSV4	Menomune (sanofi pasteur)

For additional copies, visit www.immunize.org/catg.d/p2022.pdf • Item #P2022 (4/14)

Notification of Vaccination Letter Template

Dear doctor or nurse at

Patient's primary care clinic

We recently provided vaccination services to one of your patients. We want to make certain that you have information about the vaccines we administered so you can update your patient's medical record. Please contact us if you have any questions about this information.

- \Box We provided the patient (or parent) with a written record of the vaccination(s) given.
- \Box We entered information about the vaccine(s) we administered in the regional immunization information system.

Patient's name:	Patient's birthdate:
For a child, parent's name:	Parent's birthdate:
The vaccine(s) we administered on	is/are checked below.

Hepatitis B (Engerix-B; Recombivax HB) Dose (circle one): 0.5 mL 1.0 mL	□ IPV (Polio) □ MMR
DTaP (age 6 yrs and younger)	□ Varicella (Varivax)
DTaP-HepB-IPV (Pediarix)	□ MMRV (ProQuad)
DTaP-IPV (Kinrix)	□ Hepatitis A (Havrix; Vaqta)
DTaP-IPV/Hib (Pentacel)	Dose (circle one): 0.5 mL 1.0 mL
DT (through age 6 yrs)	□ HepA-HepB (Twinrix)
☐ Tdap (age 7 yrs and older)	Human papillomavirus (HPV)
Td (age 7 yrs and older)	$\Box HPV4 (Gardasil)$
Hib (monovalent) ActHIB Hiberix PedvaxHIB	Meningococcal conjugate (MCV4) MCV4-D (Menactra) MCV4-CRM (Menveo)
☐ Hib-HepB (Comvax)	☐ Meningococcal polysaccharide (MPSV4)
Hib-MenCY (MenHibrix)	□ Influenza: Brand
Pneumococcal conjugate (PCV13)	Dose (mL)
□ Pneumococcal polysaccharide (PPSV23)	Route
Rotavirus	□ Zoster (shingles) (Zostavax)
RV1 (Rotarix)	□ Other
RV5 (RotaTeq)	

Name of clinic providing services Address City, State, Zip Contact person Email address Phone number

Technical content reviewed by the Centers for Disease Control and Prevention

IMMUNIZATION ACTION COALITION St. Paul, Minnesota • 651-647-9009 • www.vaccineinformation.org • www.immunize.org

www.immunize.org/catg.d/p3060.pdf • Item #P3060 (2/14)

Addressing Parents' Top Questions about HPV VACCINE

Parents may be interested in vaccinating, yet still have questions. Some parents might just need additional information from you, the clinician they trust. Taking the time to answer their questions and address their concerns can help parents to accept a recommendation for HPV vaccination.

WHEN PARENTS SAY:	TRY SAYING
Why does my child need the HPV vaccine?	HPV vaccine is importation vaccinated today.
What diseases are caused by HPV?	Certain HPV types car men, and in both fema with the HPV types that
Is my child really at risk for HPV?	HPV is a very commor your child from the car
Why do they need HPV vaccine at such a young age?	HPV vaccination works
I have some concerns about the safety of the vaccine—I keep reading things online that says HPV vaccination isn't safe. Do you really know if it's safe?	I know there are stories However, I want you to scientific experts. I beli With HPV vaccination headache. Sometimes We'll protect your child
Could HPV vaccine cause my child to have problems with infertility?	There is no data ava However, women wh to have children.
I'm just worried that my child will perceive this as a green light to have sex.	Numerous research st sexually active or start
How do you know if the vaccine works?	Ongoing studies are sl genital warts, and cerv
Why do boys need HPV vaccine?	HPV infection can cau HPV vaccine can help
Would you get HPV vaccine for your kids?	Yes, I have given HPV cancer-preventing vacc cancer centers, and the



IG:

portant because it prevents cancer. That is why I recommend that your daughter/son be

can cause cancer of the cervix, vagina, and vulva in females, cancer of the penis in males and males, cancers of the anus and the throat. We can help prevent infection that cause these cancers by starting the HPV vaccine series for your child today.

mon and widespread virus that infects both females and males. We can help protect cancers and diseases caused by the virus by starting HPV vaccination today.

orks best at the recommended ages of 11 or 12 years.

bries in the media and online about vaccines, and I can see how that could concern you. u to know that HPV vaccine has been carefully studied for many years by medical and believe HPV vaccine is very safe. Vaccines, like any medication, can cause side effects. ion this could include pain, swelling, and/or redness where the shot is given, or possibly mes kids faint when they get shots and they could be injured if they fall from fainting. hild by having them stay seated after the shot.

available to suggest that getting HPV vaccine will have an effect on future fertility. who develop cervical cancer could require treatment that would limit their ability

h studies have shown that getting the HPV vaccine does not make kids more likely to be tart having sex at a younger age.

e showing that HPV vaccination works very well and has decreased HPV infection, vervical precancers in young people in the years since it has been available.

cause cancers of the penis, anus, and throat in men and it can also cause genital warts. elp prevent the infection that lead to these diseases.

PV vaccine to my child (or grandchild, etc) because I believe in the importance of this accine. The American Academy of Pediatrics, the American Academy of Family Physicians, the CDC, also agree that getting the HPV vaccine is very important for your child.



PATIENT NAME

Screening Checklist for Contraindications DATE OF BIRTH _____ /___ /___ to Vaccines for Children and Teens

For parents/guardians: The following questions will help us determine which vaccines your child may be given today. If you answer "yes" to any question, it does not necessarily mean your child should not be vaccinated. It just means additional questions must be asked. If a question is not clear, please ask your healthcare provider to explain it.

yes		no	don't know
	child sick today?		
	he child have allergies to medications, food, a vaccine component, or latex?		
	e child had a serious reaction to a vaccine in the past?		
	e child had a health problem with lung, heart, kidney or metabolic disease liabetes), asthma, or a blood disorder? Is he/she on long-term aspirin therapy?		
	hild to be vaccinated is 2 through 4 years of age, has a healthcare provider u that the child had wheezing or asthma in the past 12 months?		
	child is a baby, have you ever been told he or she has had intussusception?		
	e child, a sibling, or a parent had a seizure; has the child had brain or other is system problems?		
	he child have cancer, leukemia, HIV/AIDS, or any other immune system problem?		
	past 3 months, has the child taken medications that affect the immune system s prednisone, other steroids, or anticancer drugs; drugs for the treatment of atoid arthritis, Crohn's disease, or psoriasis; or had radiation treatments?		
	past year, has the child received a transfusion of blood or blood products, n given immune (gamma) globulin or an antiviral drug?		
	child/teen pregnant or is there a chance she could become pregnant the next month?		
	e child received vaccinations in the past 4 weeks?		
DAT	FORM COMPLETED BY		
DAT	FORM REVIEWED BY		
I	e child received vaccinations in the past 4 weeks?	DAT	

It is important to have a personal record of your child's vaccinations. If you don't have one, ask the child's healthcare provider to give you one with all your child's vaccinations on it. Keep it in a safe place and bring it with you every time you seek medical care for your child. Your child will need this document to enter day care or school, for employment, or for international travel.



Technical content reviewed by the Centers for Disease Control and Prevention

Saint Paul, Minnesota • 651-647-9009 • www.immunize.org • www.vaccineinformation.org

www.immunize.org/catg.d/p4060.pdf • Item #P4060 (2/16)

for Contraindications (Children and Teens)

1. Is the child sick today? [all vaccines]

There is no evidence that acute illness reduces vaccine efficacy or increases vaccine adv events (1, 2). However, as a precaution with moderate or severe acute illness, all vac should be delayed until the illness has improved. Mild illnesses (such as otitis medi upper respiratory infections, and diarrhea) are NOT contraindications to vaccination not withhold vaccination if a person is taking antibiotics.

2. Does the child have allergies to medications, food, a vaccine component, or latex? vaccines

An anaphylactic reaction to latex is a contraindication to vaccines that contain latex component or as part of the packaging (e.g., vial stoppers, prefilled syringe plunger prefilled syringe caps). If a person has anaphylaxis after eating gelatin, do not admin vaccines containing gelatin. A local reaction to a prior vaccine dose or vaccine compo including latex, is not a contraindication to a subsequent dose or vaccine containing component. For information on vaccines supplied in vials or syringes containing lat see reference 3; for an extensive list of vaccine components, see reference 4. An egg recombinant influenza vaccine (RIV3) may be used in people age 18 years and older egg allergy of any severity who have no other contraindications. Children and teens younger than age 18 years who have experienced a serious systemic or anaphylactic tion (e.g., hives, swelling of the lips or tongue, acute respiratory distress, or collapse after eating eggs can usually be vaccinated with inactivated influenza vaccine (IIV); col ACIP recommendations (see reference 4).

3. Has the child had a serious reaction to a vaccine in the past? [all vaccines]

History of anaphylactic reaction (see question 2) to a previous dose of vaccine or va component is a contraindication for subsequent doses (1). History of encephalopat within 7 days following DTP/DTaP is a contraindication for further doses of pertuss containing vaccine. Precautions to DTaP (not Tdap) include the following: (a) seizure v 3 days of a dose, (b) pale or limp episode or collapse within 48 hours of a dose, (c) tinuous crying for 3 or more hours within 48 hours of a dose, and (d) fever of 105°F (4 within 48 hours of a previous dose. There are other adverse events that might have occurred following vaccination that constitute contraindications or precautions to fu doses. Under normal circumstances, vaccines are deferred when a precaution is pre However, situations may arise when the benefit outweighs the risk (e.g., during a co munity pertussis outbreak).

- 4. Has the child had a health problem with lung, heart, kidney, or metabolic disease diabetes), asthma, or a blood disorder? Is he/she on long-term aspirin therapy? [LAI The safety of LAIV in children and teens with lung, heart, kidney, or metabolic disea (e.g., diabetes), or a blood disorder has not been established. These conditions, inc ing asthma in children ages 5 years and older, should be considered precautions for use of LAIV. Children on long-term aspirin therapy should not be given LAIV; instea they should be given IIV.
- 5. If the child to be vaccinated is 2 through 4 years of age, has a healthcare provider you that the child had wheezing or asthma in the past 12 months? [LAIV]

Children ages 2 through 4 years who have had a wheezing episode within the past 12 m should not be given LAIV. Instead, these children should be given IIV.

6. If your child is a baby, have you ever been told that he or she has had intussuscep IRotavirus

Infants who have a history of intussusception (i.e., the telescoping of one portion of intestine into another) should not be given rotavirus vaccine.

7. Has the child, a sibling, or a parent had a seizure; has the child had brain or othe nervous system problem? [DTaP, Td, Tdap, IIV, LAIV, MMRV]

DTaP and Tdap are contraindicated in children who have a history of encephalopath within 7 days following DTP/DTaP. An unstable progressive neurologic problem is a caution to the use of DTaP and Tdap. For children with stable neurologic disorders (in ing seizures) unrelated to vaccination, or for children with a family history of seizure

REFERENCES

- 1. CDC. General recommendations on immunization, at www.cdc.gov/mmwr/pdf/rr/rr6002.
- 2. AAP. Red Book: Report of the Committee on Infectious Diseases at www.aapredbook.org.
- 3. Latex in Vaccine Packaging: www.cdc.gov/ vaccines/pubs/pinkbook/downloads/ appendices/B/latex-table.pdf
- 4. Table of Vaccine Components: www.cdc.gov/ vaccines/pubs/pinkbook/downloads/ appendices/B/excipient-table-2.pdf.

HEDIS Measures Provider Matrix - September 2017 - September 2018

Information for Healthcare Professionals about the Screening Checklist

Are you interested in knowing why we included a certain question on the screening checklist? If so, read the information below. If you want to find out even more, consult the references listed at the end.

ices vaccine efficacy or increases vaccine adverse ith moderate or severe acute illness, all vaccines proved. Mild illnesses (such as otitis media,) are NOT contraindications to vaccination. Do ing antibiotics.	vaccinate as usual (exception: children with a personal or family [i.e., parent or sibling] history of seizures generally should not be vaccinated with MMRV; they should receive separate MMR and VAR vaccines). A history of Guillain-Barré syndrome (GBS) is a con- sideration with the following: 1) Td/Tdap: if GBS has occurred within 6 weeks of a tetanus- containing vaccine and decision is made to continue vaccination, give age-appropriate Tdap instead of Td if no history of prior Tdap, to improve pertussis protection; 2) Influenza vaccine (IIV or LAIV): if GBS has occurred within 6 weeks of a prior influenza vaccination, vaccinate with IIV if at high risk for severe influenza complications.
ons, food, a vaccine component, or latex? [all	
raindication to vaccines that contain latex as a .g., vial stoppers, prefilled syringe plungers, aphylaxis after eating gelatin, do not administer n to a prior vaccine dose or vaccine component, o a subsequent dose or vaccine containing that supplied in vials or syringes containing latex, scine components, see reference 4. An egg-free y be used in people age 18 years and older with her contraindications. Children and teens rienced a serious systemic or anaphylactic reachgue, acute respiratory distress, or collapse) with inactivated influenza vaccine (IIV); consult	8. Does the child have cancer, leukemia, HIV/AIDS, or any other immune system problem? [LAIV, MMR, MMRV, RV, VAR] Live virus vaccines (e.g., MMR, MMRV, varicella, rotavirus, and the intranasal live, attenu- ated influenza vaccine [LAIV]) are usually contraindicated in immunocompromised chil- dren. However, there are exceptions. For example, MMR is recommended for asymptomatic HIV-infected children who do not have evidence of severe immunosuppression. Likewise, varicella vaccine should be considered for HIV-infected children with age-specific CD4+ T-lymphocyte percentage at 15% or greater and may be considered for children age 8 years and older with CD4+ T-lymphocyte counts of greater than or equal to 200 cells/µL. Immunosuppressed children should not receive LAIV. Infants who have been diagnosed with severe combined immunodeficiency (SCID) should not be given a live virus vaccine, including rotavirus (RV) vaccine. Other forms of immunosuppression are a precaution, not a contraindication, to rotavirus vaccine. For details, consult the ACIP recommendations (1, 6, 7, 8).
a vaccine in the past? [all vaccines] stion 2) to a previous dose of vaccine or vaccine equent doses (1). History of encephalopathy ntraindication for further doses of pertussis-	9. In the past 3 months, has the child taken medications that affect the immune system such as prednisone, other steroids, or anticancer drugs; drugs for the treatment of rheumatoid arthritis, Crohn's disease, or psoriasis; or had radiation treatments? [LAIV, MMR, MMRV, VAR]
tot Tdap) include the following: (a) seizure within or collapse within 48 hours of a dose, (c) con- t8 hours of a dose, and (d) fever of 105°F (40°C) are other adverse events that might have itute contraindications or precautions to future cines are deferred when a precaution is present. penefit outweighs the risk (e.g., during a com-	Live virus vaccines (e.g., LAIV, MMR, VAR, ZOS) should be postponed until after chemo- therapy or long-term high-dose steroid therapy has ended. For details and length of time to postpone, consult the ACIP statement (1). Some immune mediator and immune modu- lator drugs (especially the antitumor-necrosis factor agents adalimmab, infliximab, and etanercept) may be immunosuppressive. The use of live vaccines should be avoided in persons taking these drugs (MMWR 2011;60 [RR2]:23). To find specific vaccination schedules for stem cell transplant (bone marrow transplant) patients, see reference 9. LAIV can be given only to healthy non-pregnant people ages 2 through 49 years.
lung, heart, kidney, or metabolic disease (e.g., he/she on long-term aspirin therapy? [LAIV] <i>it</i> th lung, heart, kidney, or metabolic disease ot been established. These conditions, includ- lder, should be considered precautions for the n therapy should not be given LAIV; instead,	10. In the past year, has the child received a transfusion of blood or blood products, or been given immune (gamma) globulin or an antiviral drug? [LAIV, MMR, MMRV, VAR] Certain live virus vaccines (e.g., LAIV, MMR, MMRV, varicella) may need to be deferred, depending on several variables. Consult the most current ACIP recommendations or the current Red Book for the most current information on intervals between antiviral drugs, immune globulin or blood product administration and live virus vaccines (1, 2).
4 years of age, has a healthcare provider told ma in the past 12 months? [LAIV] ad a wheezing episode within the past 12 months children should be given IIV.	11. Is the child/teen pregnant or is there a chance she could become pregnant during the next month? [LAIV, MMR, MMRV, VAR] Live virus vaccines (e.g., MMR, MMRV, varicella, LAIV) are contraindicated one month before and during pregnancy because of the theoretical risk of virus transmission to the fetus (1, 2). Sexually active young women who receive a live virus vaccine should be instructed to practice careful contraception for one month following receipt of the vaccine
tion (i.e., the telescoping of one portion of the n rotavirus vaccine.	(7, 10). On theoretical grounds, inactivated poliovirus vaccine should not be given during pregnancy; however, it may be given if risk of exposure is imminent (e.g., travel to endemic areas) and immediate protection is needed. Use of Td or Tdap is not contraindicated in pregnancy. At the provider's discretion, either vaccine may be administered during the 2nd or 3rd trimester (5, 11)
a seizure; has the child had brain or other ap, IIV, LAIV, MMRV] Idren who have a history of encephalopathy stable progressive neurologic problem is a pre- children with stable neurologic disorders (includ- for children with a family history of seizures,	12. Has the child received vaccinations in the past 4 weeks? <i>[LAIV, MMR, MMRV, VAR, yellow fever]</i> Children who were given either LAIV or an injectable live virus vaccine (e.g., MMR, MMRV, varicella, yellow fever) should wait 28 days before receiving another vaccination of this type. Inactivated vaccines may be given at the same time or at any spacing interval.
 CDC. Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), United States, 2015–16 Influenza Season at www.cdc.gov/mmwr/pdf/wk/mm6430.pdf, pages 818–825. CDC. Measles, mumps, and rubella – vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps. MMWR 1998; 47 (RR-8). 	 CDC, Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices. MMWR 2007; 56 (RR-4). Rubin LG, Levin MJ, Ljungman P. 2013 IDSA Clinical practice guideline for vaccination of the immunocompromised host. Clinical Infectious Diseases 2014;S8(3):e44–100. Tomblyn M, Einsele H, et al. Guidelines for pre- venting infectious complications among hemato- poietic stem cell transplant recipients: a global perspective. BiolBloodMarrow Transplant 15:1143- 238; 2009 at www.cdc.gov/vaccines/pubs/ hemato-cell-transplts.htm. CDC. Notice to readers: Revised ACIP recom- mendation for avoiding pregnancy after receiv- ing a rubella-containing vaccine. MMWR 2001; 50 (49). CDC. Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants: Recommendations of the ACIP. MMWR 2008; 57 (RR-4).
Saint Paul, Minnesota • 651-647-90	09 • www.immunize.org • www.vaccineinformation.org

Immunization Action Coalition • Saint Paul, Minnesota • 651-647-9009 • www.immunize.org • www.vaccineinformation.org

www.immunize.org/catg.d/p4060.pdf • Item #P4060 - page 2 (2/16)

2 to 20 years: Boys Body mass index-for-age percentiles

NAME

RECORD #



Published May 30, 2000 (modified 10/16/00). SOURCE: Developed by the National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000). http://www.cdc.gov/growthcharts





SOURCE: Developed by the National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000). http://www.cdc.gov/growthcharts

()) DX(SAFER · HEALTHIER · PEOPLE



at 1-800-331-3843.

You may have relevant information regarding a member that you are unable to submit via claim. In this case, you can close the gap by submitting the medical record indicating the member has already received the relevant service or has a condition that excludes them from the measure. All medical records should be faxed to **AvMed Corporate Quality Improvement**